Insider Selling: Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells 345,942 Shares of Stock
by Kim Johansen · The Markets DailySangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) SVP Nathalie Dubois-Stringfellow sold 345,942 shares of Sangamo Therapeutics stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $0.26, for a total transaction of $89,944.92. Following the transaction, the senior vice president owned 332,769 shares in the company, valued at $86,519.94. The trade was a 50.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Sangamo Therapeutics Stock Performance
Shares of NASDAQ:SGMO traded down $0.00 during midday trading on Thursday, hitting $0.26. 7,121,911 shares of the company’s stock traded hands, compared to its average volume of 6,359,448. The company has a market cap of $105.64 million, a PE ratio of -0.58 and a beta of 1.49. The firm’s fifty day moving average price is $0.34 and its two-hundred day moving average price is $0.44. Sangamo Therapeutics, Inc. has a twelve month low of $0.21 and a twelve month high of $0.84.
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last posted its earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.12). The business had revenue of $14.23 million for the quarter, compared to analyst estimates of $40.25 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative return on equity of 2,662.06%. As a group, equities research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.17 EPS for the current fiscal year.
Institutional Investors Weigh In On Sangamo Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. World Investment Advisors increased its stake in Sangamo Therapeutics by 88.5% during the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 20,000 shares during the period. Cetera Investment Advisers purchased a new stake in Sangamo Therapeutics during the 4th quarter worth $31,000. XTX Topco Ltd purchased a new stake in Sangamo Therapeutics during the 2nd quarter worth $41,000. Engineers Gate Manager LP increased its stake in Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 44,078 shares during the period. Finally, State of Wyoming purchased a new stake in Sangamo Therapeutics during the 4th quarter worth $47,000. Hedge funds and other institutional investors own 56.92% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on SGMO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. Zacks Research lowered shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. Wall Street Zen lowered shares of Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, February 10th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $5.50.
View Our Latest Research Report on Sangamo Therapeutics
About Sangamo Therapeutics
Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.
Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.